Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 986 across all filing types
Latest filing 2016-09-06 Board/Management Inform…
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 6, 2016. The content focuses on the appointment of a new Chief Financial Officer, Christophe Couturier, including details about his employment terms, compensation, and stock options. It also mentions the resignation of the previous CFO. The key section is Item 5.02, which relates to departure and appointment of directors or certain officers. There are no financial statements or earnings data presented, nor is this a report of voting results or a regulatory announcement unrelated to management changes. The document fits the category of Board/Management Information (MANG) as it announces changes in senior management. The document length (8295 characters) is sufficient to contain detailed information, not just a brief announcement or certification, supporting this classification.
2016-09-06 English
10-Q
Interim / Quarterly Report Q2 2016
2016-08-04 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 4, 2016, reporting the company's financial results for the quarter ended June 30, 2016. It includes a press release as an exhibit announcing these results. The document explicitly states it is a Current Report on Form 8-K and not a full quarterly or annual report. The content corresponds to an initial announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). The document length is 3124 characters, which is typical for an 8-K earnings announcement rather than a full interim report. Therefore, the correct classification is Earnings Release (ER).
2016-08-04 English
FORM 4 -
Director's Dealing
2016-07-05 English
FORM 4 -
Director's Dealing
2016-07-05 English
FORM 4 -
Director's Dealing
2016-07-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.